Table 3 Univariate analysis for PFS and OS

From: PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer

 

Hazard ratio

95% CI

P -value

PFS

 PKM2 expression (high vs low)

1.89

1.48–2.27

0.003

 PS (2 vs 0–1)

2.64

1.89–3.17

0.001

 Age (>70 vs ⩽70 years)

1.24

0.87–1.62

0.77

 Gender (male vs female)

1.19

0.84–1.41

0.51

 Stage (IV vs IIIB)

1.77

1.11–2.31

0.03

 Histology (squamous vs non-squamous)

1.32

0.85–1.54

0.61

 Tumour differentiation (low vs well-moderate)

1.41

0.90–1.77

0.14

OS

 PKM2 expression (high vs low)

1.93

1.54–2.46

0.002

 PS (2 vs 0–1)

2.87

1.92–3.44

<0.001

 Age (>70 vs ⩽70 years)

1.35

0.91–1.88

0.23

 Gender (male vs female)

1.16

0.81–1.33

0.48

 Stage (IV vs IIIB)

1.45

0.96–1.85

0.17

 Histology (squamous vs non-squamous)

1.17

0.89–1.28

0.94

 Tumour differentiation (low vs well-moderate)

1.32

0.87–1.32

0.31

  1. Abbreviations: CI=confidence interval; OS=overall survival; PFS=progression-free survival; PS=performance status.
Back to article page